ERBB2 and breast carcinoma: It is known that overexpression of HER2 is found in about 20% of breast cancer patients, leading to aberrant signaling of the PI3K/Akt and MEK/Erk pathways, and is correlated with malignant transformation, chemotherapy resistance and poor prognosis.1, 6, 7 Meanwhile, aberrant EGFR activity was also observed during pathogenesis and progression of lung and breast cancers.8, 9 Therefore, a promising approach may lie in the development of chemotherapeutic strategies exploiting the deregulation of target ERBB to create cancer treatments with both preventive and therapeutic potential.